State Street
ZBIO

State Street’s Zenas BioPharma ZBIO Stock Holding History

State Street’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.2M Buy
2,055,100
+584,177
+40% +$11.6M ﹤0.01% 1818
2026
Q1 		$28.8M Buy
1,470,923
+1,032,629
+236% +$23.2M ﹤0.01% 2042
2025
Q4 		$15.9M Buy
438,294
+60,809
+16% +$2M ﹤0.01% 2382
2025
Q3 		$8.38M Buy
377,485
+67,249
+22% +$1.09M ﹤0.01% 2731
2025
Q2 		$3.01M Buy
310,236
+44,036
+17% +$429K ﹤0.01% 3168
2025
Q1 		$2.1M Buy
266,200
+54,694
+26% +$428K ﹤0.01% 3227
2024
Q4 		$1.73M Buy
+211,506
New +$3.3M ﹤0.01% 3362

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

State Street's ZBIO Position: Q2 2026 in Review

State Street increased its Zenas BioPharma (ZBIO) stake by 40% in Q2 2026, buying an estimated $11.6M and bringing the position to 2,055,100 shares worth $52.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

State Street first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • State Street held 2,055,100 shares of Zenas BioPharma worth $52.2M as of Q2 2026.
  • State Street bought 584,177 Zenas BioPharma shares in Q2 2026, an estimated $11.6M.
  • Zenas BioPharma made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1818 holding.
  • State Street first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.